Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

January is “National Radon Action Month” and state and local health departments are encouraging everyone to test their homes ...

Since 2023, seven babies in the neonatal intensive care unit of a Richmond hospital have suffered unexplained fractures and ...